Literature DB >> 31781931

Multiparametric MRI and 18F-FDG PET features for differentiating gastrointestinal stromal tumors from benign gastric subepithelial lesions.

Jeongin Yoo1, Se Hyung Kim2,3,4, Joon Koo Han1,5,6.   

Abstract

OBJECTIVES: To investigate whether multiparametric magnetic resonance imaging (MRI) and 18F-fluorodeoxyglucose positron emission tomography (PET) can be helpful in differentiating gastrointestinal stromal tumors (GISTs) from non-GISTs and high-risk GISTs from low-risk GISTs.
METHODS: This retrospective study included 56 patients with pathologically confirmed GISTs (n = 39), leiomyoma (n = 8), schwannoma (n = 5), heterotopic pancreas (n = 3), and glomus tumor (n = 1) who underwent MRI and/or PET examinations. Two radiologists reviewed MRI regarding location, shape, contour, growth pattern, margin, signal intensity (SI) on T1- (T1WI) and T2-weighted images (T2WI), degree and pattern of enhancement, hemorrhage, and necrosis. Mean apparent diffusion coefficient (ADC) and maximum standardized uptake value (SUVmax) were measured. Imaging features were compared among non-GISTs, low-risk GISTs, and high-risk GISTs using uni- and multivariate statistical analyses.
RESULTS: Size, longitudinal location, shape, contour, growth pattern, SI on T1- and T2WI, enhancement pattern, hemorrhage, necrosis, ADC, and SUVmax were significantly different among non-GISTs, low-risk GISTs, and high-risk GISTs (p < 0.05). On multivariate analysis, SI on T2WI (hazard ratio [HR], 66.0; p = 0.002) was the only independent variable for differentiating GISTs from non-GISTs whereas enhancement pattern (HR, 56.0; p = 0.041), ADC (HR, 0.997; p = 0.01), and SUVmax (HR, 2.08; p = 0.027) were significant features for differentiating between high-risk and low-risk GISTs.
CONCLUSIONS: Several qualitative and quantitative MRI and PET features including ADC and SUVmax values are significantly different among non-GISTs, low-risk GISTs, and high-risk GISTs. Multiparametric information obtained from MRI with or without PET can be useful for differentiation of gastric subepithelial tumors as well as for determining patients' management and prognosis. KEY POINTS: • Several qualitative MRI features are helpful in distinguishing gastrointestinal stromal tumors (GISTs) from non-GISTs as well as high-risk GISTs from low-risk GISTs. • Apparent diffusion coefficient value on diffusion-weighted imaging can be useful in distinguishing GISTs from non-GISTs as well as high-risk GISTs from low-risk GISTs. • PET has the potential to distinguish between high-risk and low-risk GISTs.

Entities:  

Keywords:  Diffusion magnetic resonance imaging; Gastrointestinal stromal tumors; Magnetic resonance imaging; Positron-emission tomography; Stomach neoplasms

Mesh:

Substances:

Year:  2019        PMID: 31781931     DOI: 10.1007/s00330-019-06534-9

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  4 in total

Review 1.  Gastrointestinal stromal tumors: a comprehensive radiological review.

Authors:  Akitoshi Inoue; Shinichi Ota; Michio Yamasaki; Bolorkhand Batsaikhan; Akira Furukawa; Yoshiyuki Watanabe
Journal:  Jpn J Radiol       Date:  2022-07-09       Impact factor: 2.374

2.  [18F]FAPI-42 PET/CT versus [18F]FDG PET/CT for imaging of recurrent or metastatic gastrointestinal stromal tumors.

Authors:  Chunhui Wu; Xinhua Zhang; Yu Zeng; Renbo Wu; Li Ding; Yanzhe Xia; Zhifeng Chen; Xiangsong Zhang; Xiaoyan Wang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-08-30       Impact factor: 10.057

3.  Glomus tumor of the duodenum: a rare case report.

Authors:  Shin Sasaki; Yuko Takami; Yoshiyuki Wada; Tomoki Ryu; Hajime Imamura; Hiroki Ureshino; Minako Fujiwara; Hideki Saitsu
Journal:  Surg Case Rep       Date:  2020-12-03

4.  Utility of noncontrast MRI in the detection and risk grading of gastrointestinal stromal tumor: a comparison with contrast-enhanced CT.

Authors:  Ziling Zhou; Jingyu Lu; John N Morelli; Daoyu Hu; Zhen Li; Peng Xiao; Xuemei Hu; Yaqi Shen
Journal:  Quant Imaging Med Surg       Date:  2021-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.